Khay-Lin Teoh

Dr Khay-Lin Teoh

Chief Operating Officer
Company Secretary

As Chief Operating Officer and Company Secretary, Khay-Lin leads and manages the Institute’s Research Support function and staff to facilitate the delivery of quality services which support the Institute in meeting its strategic, operational, compliance, and risk management objectives.

With a background combining governance, business management and science, Khay-Lin takes an analytical and rational approach to management and brings a wealth of experience and insight to the position. His skills and experience include governance, strategic planning and risk management, financial management, human resource management, business planning and development, procurement and contract negotiations, and research management.

Khay-Lin has worked in both the for-profit sector (ASX listed company) and for-purpose sector (higher education, medical research) and for the last 16 years in the medical research industry.

He has a PhD, MBA and is a member of the AICD.

Prof Hui Gan

Prof Hui Gan

Clinical Research Lead (ONJCRI Executive Team)
Clinician Scientist, Tumour Targeting Laboratory
Co-Director, Centre for Research Excellence in Brain Cancer
Director, Cancer Clinical Trials Centre, Austin Health

I completed a Bachelor of Medicine and Bachelor of Surgery at the University of Melbourne before training in the care of cancer patients and becoming a Fellow of The Royal Australasian College of Physicians (Medical Oncology). I have a PhD from the University of Melbourne (Medicine), as well having completed Drug Development Fellowship at the Princess Margaret Hospital, Toronto.

As a clinician at Austin Health, my main areas of responsibility are to care and manage patients with solid malignancies, particularly those with  tumours of the brain, and head and neck. I also lead the Phase 1 Program for patients seeking novel treatments after they have exhausted standard of care treatments. In addition to direct patient care, I am the Medical Director for Cancer Clinical Trials at the Austin Hospital.

As a clinician-scientist at the ONJCRI, my research interests include the development of novel drugs for cancer patients, especially those with brain tumours. Whilst working with many types of biological treatments, a key focus are the development of novel antibody based treatments, particularly those targeting tumour specific targets on the tumour surface and tumour microenvironment. I have played a substantial role in the translation of many such drugs into the clinic, including several targeting the ErbB and Eph receptor tyrosine kinases.

Prof Matthias Ernst

Prof Matthias Ernst

Director, ONJCRI
Head, Cancer and Inflammation Program
Head, Cancer and Inflammation Laboratory
Head, School of Cancer Medicine, La Trobe University

Conducting research in close proximity to clinicians provides my group with an opportunity to use our scientific curiosity to address the most urgent needs of cancer patients.

After gaining my PhD at the Swiss Institute of Technology (ETH) in Zürich, Switzerland, I received postdoctoral training at the Merck Sharp & Dohme Research Laboratories in Pennsylvania in the area of bone biology.

With the aim of extending my studies into the molecular mechanisms which underpin the growth of cancer cells, I joined Prof Ashley Dunn’s laboratory at the Melbourne-Parkville Branch of the Ludwig Institute for Cancer Research (LICR).

In 1996, I returned to Switzerland, to join Novartis as the Deputy Head for Bone Biology Research Department. I was invited back to LICR in 1998 as Group Leader and was appointed Acting Director in 2009.

In 2012, I moved to the Walter and Eliza Hall Institute, where I continued to explore state-of-the-art molecular biology and genetic tools to understand mechanisms which corrupt the normal renewal of the lining of the bowel and stomach, resulting in tumour formation. I  joined ONJCRI in late 2014 and my laboratory team explores novel strategies to target mechanisms by which tumour cells and normal cells communicate and develop new treatments for gastrointestinal cancers.